This is not the most recent version of the article. View current version (4 NOV 2013)
Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease
Editorial Group: Cochrane Airways Group
Published Online: 24 JAN 2007
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
How to Cite
Arandjus C, Black PN, Poole P. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease (Protocol). Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD002309. DOI: 10.1002/14651858.CD002309.pub2.
- Publication Status: Edited (no change to conclusions)
- Published Online: 24 JAN 2007
This is not the most recent version of the article. View current version (04 NOV 2013)
This is the protocol for a review and there is no abstract. The objectives are as follows:
To evaluate the safety and efficacy of PDE4 inhibitors in the management of stable chronic obstructive pulmonary disease (COPD). Outcomes to be assessed will include lung function, quality of life, clinical outcomes, symptoms, functional exercise capacity, and adverse effects.